logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

Press Releases

Navigation Toggle Navigation
  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Dec 2, 2020

PharmaCyte Biotech Successfully Completes 9-Month Stability Study

  • Nov 4, 2020

PharmaCyte Biotech Receives U.S. FDA Clinical Hold Letter

  • Oct 2, 2020

PharmaCyte Biotech’s Investigational New Drug Application Placed on Hold by the U.S. FDA

  • Sep 23, 2020

PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period

  • Sep 14, 2020

PharmaCyte Biotech Successfully Completes Six-Month Stability Study

  • Sep 8, 2020

PharmaCyte Biotech Successfully Completes Second Container Closure Integrity Test

  • Sep 2, 2020

PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer

  • Aug 10, 2020

PharmaCyte Biotech Appoints Dr. José Iglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic Cancer

  • Aug 5, 2020

FDA Formally Accepts PharmaCyte Biotech’s Drug Master File for Company’s Pancreatic Cancer Therapy

  • Jul 29, 2020

PharmaCyte Biotech Receives CE Mark for Licensed COVID-19 Molecular Tests

RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...29
  • Next »

Contact Us

PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada 89169
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value October 7, 2022
  • PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital August 15, 2022